[go: up one dir, main page]

CL2008001943A1 - Compuestos derivados de fenil-triazol, inhibidores de enzimas de señales especificas que participan del control de la proliferacion celular; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer, infecciones, enfermedades inflamatorias y autoinmunes. - Google Patents

Compuestos derivados de fenil-triazol, inhibidores de enzimas de señales especificas que participan del control de la proliferacion celular; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer, infecciones, enfermedades inflamatorias y autoinmunes.

Info

Publication number
CL2008001943A1
CL2008001943A1 CL2008001943A CL2008001943A CL2008001943A1 CL 2008001943 A1 CL2008001943 A1 CL 2008001943A1 CL 2008001943 A CL2008001943 A CL 2008001943A CL 2008001943 A CL2008001943 A CL 2008001943A CL 2008001943 A1 CL2008001943 A1 CL 2008001943A1
Authority
CL
Chile
Prior art keywords
compounds
infections
inflammatory
triazole
pharmaceutical composition
Prior art date
Application number
CL2008001943A
Other languages
English (en)
Inventor
Peter Ettmayer
Steffen Steurer
Ioannis Sapountzis
Christian Klein
Andreas Mantoulidis
Irene Waizenegger
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38792475&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008001943(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CL2008001943A1 publication Critical patent/CL2008001943A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Compuestos derivados de triazol; composición farmacéutica que comprende a dichos compuestos; y su uso para tratar cáncer, infecciones, enfermedades inflamatorias y autoinmunes.
CL2008001943A 2007-07-02 2008-06-30 Compuestos derivados de fenil-triazol, inhibidores de enzimas de señales especificas que participan del control de la proliferacion celular; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer, infecciones, enfermedades inflamatorias y autoinmunes. CL2008001943A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07111566 2007-07-02

Publications (1)

Publication Number Publication Date
CL2008001943A1 true CL2008001943A1 (es) 2009-09-11

Family

ID=38792475

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008001943A CL2008001943A1 (es) 2007-07-02 2008-06-30 Compuestos derivados de fenil-triazol, inhibidores de enzimas de señales especificas que participan del control de la proliferacion celular; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer, infecciones, enfermedades inflamatorias y autoinmunes.

Country Status (21)

Country Link
US (1) US8889665B2 (es)
EP (1) EP2173734B1 (es)
JP (1) JP5511658B2 (es)
KR (1) KR20100039849A (es)
CN (1) CN101796045A (es)
AR (1) AR067397A1 (es)
AU (1) AU2008270300A1 (es)
BR (1) BRPI0814601A2 (es)
CA (1) CA2692383A1 (es)
CL (1) CL2008001943A1 (es)
CO (1) CO6251316A2 (es)
EA (1) EA201000105A1 (es)
EC (1) ECSP099823A (es)
IL (1) IL202625A0 (es)
MA (1) MA32120B1 (es)
MX (1) MX2009013935A (es)
PE (1) PE20090837A1 (es)
TN (1) TN2009000551A1 (es)
TW (1) TW200911789A (es)
UY (1) UY31198A1 (es)
WO (1) WO2009003999A2 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2041116A1 (de) 2006-07-07 2009-04-01 Boehringer Ingelheim International GmbH Phenyl substituierte heteroaryl-derivate und deren verwendung als antitumormittel
US20100240657A1 (en) * 2007-07-02 2010-09-23 Boehringer Ingelheim International Gmbh Chemical compounds
CL2008001943A1 (es) 2007-07-02 2009-09-11 Boehringer Ingelheim Int Compuestos derivados de fenil-triazol, inhibidores de enzimas de señales especificas que participan del control de la proliferacion celular; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer, infecciones, enfermedades inflamatorias y autoinmunes.
TW201014860A (en) 2008-09-08 2010-04-16 Boehringer Ingelheim Int New chemical compounds
PE20110294A1 (es) 2008-09-29 2011-05-26 Boehringer Ingelheim Int Compuestos heterociclicos como inhibidores de enzimas de senal especifica
CA2752265A1 (en) 2009-02-17 2010-08-26 Boehringer Ingelheim International Gmbh Pyrimido [5,4-d] pyrimidine derivatives for the inhibition of tyrosine kinases
JP2010235575A (ja) * 2009-03-09 2010-10-21 Konica Minolta Holdings Inc 含窒素縮合複素環化合物の製造方法
DE102009019962A1 (de) * 2009-05-05 2010-11-11 Merck Patent Gmbh 3-([1,2,3]Triazol-4-yl)-pyrrolo[2,3-b]pyridinderivate
US8865703B2 (en) 2010-03-26 2014-10-21 Boehringer Ingelheim International Gmbh Pyridyltriazoles
EP2552905B1 (en) 2010-03-26 2016-10-05 Boehringer Ingelheim International GmbH B-Raf kinase inhibitors
UY33817A (es) 2010-12-21 2012-07-31 Boehringer Ingelheim Int ?nuevas oxindolpirimidinas bencílicas?.
US8710055B2 (en) 2010-12-21 2014-04-29 Boehringer Ingelheim International Gmbh Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors
US8889684B2 (en) 2011-02-02 2014-11-18 Boehringer Ingelheim International Gmbh Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors
US9156837B2 (en) 2011-07-29 2015-10-13 Takeda Pharmaceutical Company Limited Heterocyclic compound
CN103172617A (zh) * 2011-12-20 2013-06-26 天津市国际生物医药联合研究院 1,5-二取代-1,2,3-三氮唑三氟甲基类化合物的应用
CN103539784B (zh) * 2012-07-09 2016-08-17 中国科学院广州生物医药与健康研究院 杂环苯甲酰胺类化合物、药用组合物及其应用
WO2015143654A1 (en) * 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
WO2015143652A1 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
WO2015143653A1 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
WO2016161572A1 (en) 2015-04-08 2016-10-13 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
WO2016198691A1 (en) 2015-06-11 2016-12-15 Basilea Pharmaceutica Ag Efflux-pump inhibitors and therapeutic uses thereof
KR101723881B1 (ko) * 2016-03-28 2017-04-07 이화여자대학교 산학협력단 신규한 트리아졸 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 오로라 키나제 관련 약학적 조성물
JP7391055B2 (ja) * 2018-07-04 2023-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｇｐｒ１４２アゴニストとしてのトリアゾールベンズアミド誘導体
CN115884965B (zh) * 2020-05-07 2025-09-26 拉姆巴姆医疗技术有限公司 用于治疗ApoL1相关疾病的组合物
CN116761801A (zh) * 2021-03-12 2023-09-15 四川科伦博泰生物医药股份有限公司 具有蛋白激酶抑制活性的杂环化合物、包含其的药物组合物及其制备方法和用途
CN119300807A (zh) * 2022-04-19 2025-01-10 沃特谢德医疗公司 用于治疗泌尿系统紊乱的制剂
CN114805334B (zh) * 2022-05-24 2023-06-09 深圳大学 一种QC和GSK-3β多靶向抑制剂及其制备方法与应用
EP4648851A1 (en) * 2023-01-10 2025-11-19 Astrazeneca AB Substituted (hetero)anilines and their use
CN116068110B (zh) * 2023-01-19 2024-11-22 武汉大学 叠氮质谱探针的合成方法及应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU507066B1 (en) * 1977-09-06 1980-01-31 Sumitomo Chemical Company, Limited 2-Substituted-5-Hydroxy-1h-Imidazole 4-Carbozamide Derivatives
JPH03174153A (ja) 1989-09-20 1991-07-29 Fuji Photo Film Co Ltd カラー画像形成方法
WO1996023783A1 (en) * 1995-02-02 1996-08-08 Smithkline Beecham Plc Indole derivatives as 5-ht receptor antagonist
WO1997003967A1 (en) 1995-07-22 1997-02-06 Rhone-Poulenc Rorer Limited Substituted aromatic compounds and their pharmaceutical use
US6492403B1 (en) * 1999-02-09 2002-12-10 3-Dimensional Pharmaceuticals, Inc. Methods of treating C1s-mediated diseases and conditions and compositions thereof
UA71971C2 (en) 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
US6531478B2 (en) 2000-02-24 2003-03-11 Cheryl P. Kordik Amino pyrazole derivatives useful for the treatment of obesity and other disorders
JP2002069070A (ja) * 2000-04-07 2002-03-08 Takeda Chem Ind Ltd 複素環化合物、その製造法および用途
EP1364949A4 (en) 2001-02-02 2005-11-23 Takeda Pharmaceutical JNK INHIBITOR
US7223782B2 (en) 2001-11-01 2007-05-29 Icagen, Inc. Pyrazole-amides and -sulfonamides
US20040010027A1 (en) 2001-12-17 2004-01-15 Pharmacia & Upjohn Spa Hydroxphenyl-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical comositions comprising them
JP2005162612A (ja) 2002-01-09 2005-06-23 Ajinomoto Co Inc アシルスルホンアミド誘導体
ATE329909T1 (de) * 2002-11-27 2006-07-15 Boehringer Ingelheim Pharma 1,2,3-triazolamid-derivate als cytokininhibitoren
SG146624A1 (en) 2003-09-11 2008-10-30 Kemia Inc Cytokine inhibitors
WO2005030704A1 (en) 2003-09-24 2005-04-07 Methylgene, Inc. Inhibitors of histone deacetylase
WO2005040152A1 (en) 2003-10-20 2005-05-06 E.I. Dupont De Nemours And Company Heteroyclylphenyl-and heterocyclylpyridyl-substituted azolecarboxamides as herbicides
JP4824576B2 (ja) 2003-12-03 2011-11-30 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド サイトカイン生成のインヒビターとしての１，２，３−トリアゾールアミド誘導体
ES2327940T3 (es) * 2004-03-09 2009-11-05 Boehringer Ingelheim Pharmaceuticals Inc. 3-(4-heterociclil-1,2,3-triazol-1-il)-n-aril-benzamidas en calidad de inhibidores de la produccion de citocinas para el tratamiento de enfermedades inflamatorias cronicas.
US7485657B2 (en) * 2004-05-12 2009-02-03 Boehringer Ingelheim Pharmaceuticals, Inc. Anti-cytokine heterocyclic compounds
AU2005304393B2 (en) 2004-11-10 2012-09-27 Synta Pharmaceuticals Corp. IL-12 modulatory compounds
US7531560B2 (en) * 2004-11-10 2009-05-12 Boehringer Ingelheim Pharmaceuticals, Inc. Anti-cytokine heterocyclic compounds
US7625931B2 (en) * 2005-01-14 2009-12-01 Cgi Pharmaceuticals, Inc. Certain substituted diphenyl ureas, as modulators of kinase activity
JP2007076376A (ja) * 2005-09-09 2007-03-29 Yanmar Co Ltd トラクタ
WO2007056016A2 (en) 2005-11-02 2007-05-18 Kemia, Inc. Bisamide cytokine inhibitors
WO2007075896A2 (en) 2005-12-22 2007-07-05 Kemia, Inc. Heterocyclic cytokine inhibitors
WO2007076474A1 (en) 2005-12-23 2007-07-05 Kalypsys, Inc. Novel substituted pyridinyloxy and pyrimidinyloxy amides useful as inhibitors of protein kinases
CA2647266A1 (en) * 2006-04-18 2007-10-25 Boehringer Ingelheim International Gmbh Process for making cytokine inhibiting compounds containing 4- and 5- imidazolyl rings and the intermediates thereof
AR060890A1 (es) 2006-05-15 2008-07-23 Boehringer Ingelheim Int Compuestos derivados de pirimidina y composicion farmaceutica en base a ellos
US8030487B2 (en) * 2006-07-07 2011-10-04 Targegen, Inc. 2-amino—5-substituted pyrimidine inhibitors
JP5185930B2 (ja) * 2006-07-07 2013-04-17 ブリストル−マイヤーズ スクイブ カンパニー ピロロトリアジンキナーゼ阻害剤
EP2041116A1 (de) * 2006-07-07 2009-04-01 Boehringer Ingelheim International GmbH Phenyl substituierte heteroaryl-derivate und deren verwendung als antitumormittel
AR061829A1 (es) * 2006-07-07 2008-09-24 Schering Corp Ciclobuten-1, 2-dionas 3,4-di sustituidas como ligandos de receptores de quimiocinas cxc
PE20080906A1 (es) 2006-08-17 2008-07-05 Kemia Inc Derivados heteroarilo como inhibidores de citocina
WO2008079909A1 (en) 2006-12-21 2008-07-03 Plexxikon, Inc. Pyrrolo [2,3-b] pyridines as kinase modulators
WO2008089034A2 (en) 2007-01-11 2008-07-24 Kemia, Inc. Cytokine inhibitors
EP2132177B1 (en) 2007-03-01 2013-07-17 Novartis AG Pim kinase inhibitors and methods of their use
US20100240657A1 (en) * 2007-07-02 2010-09-23 Boehringer Ingelheim International Gmbh Chemical compounds
CL2008001943A1 (es) 2007-07-02 2009-09-11 Boehringer Ingelheim Int Compuestos derivados de fenil-triazol, inhibidores de enzimas de señales especificas que participan del control de la proliferacion celular; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer, infecciones, enfermedades inflamatorias y autoinmunes.
MX2010000617A (es) 2007-07-17 2010-05-17 Plexxikon Inc Compuestos y metodos para modulacion de cinasa, e indicaciones de estos.
WO2010010154A1 (en) 2008-07-24 2010-01-28 Nerviano Medical Sciences S.R.L. 3,4-diarylpyrazoles as protein kinase inhibitors
TW201014860A (en) * 2008-09-08 2010-04-16 Boehringer Ingelheim Int New chemical compounds
PE20110294A1 (es) 2008-09-29 2011-05-26 Boehringer Ingelheim Int Compuestos heterociclicos como inhibidores de enzimas de senal especifica
CA2752265A1 (en) 2009-02-17 2010-08-26 Boehringer Ingelheim International Gmbh Pyrimido [5,4-d] pyrimidine derivatives for the inhibition of tyrosine kinases
EP2552905B1 (en) 2010-03-26 2016-10-05 Boehringer Ingelheim International GmbH B-Raf kinase inhibitors
US8865703B2 (en) 2010-03-26 2014-10-21 Boehringer Ingelheim International Gmbh Pyridyltriazoles
US8710055B2 (en) 2010-12-21 2014-04-29 Boehringer Ingelheim International Gmbh Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors
US20130023531A1 (en) 2011-01-27 2013-01-24 Boehringer Ingelheim International Gmbh Pyrimido[5,4-d]pyrimidylamino phenyl sulfonamides as serine/threonine kinase inhibitors
US8889684B2 (en) 2011-02-02 2014-11-18 Boehringer Ingelheim International Gmbh Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors

Also Published As

Publication number Publication date
JP5511658B2 (ja) 2014-06-04
EP2173734A2 (en) 2010-04-14
WO2009003999A3 (en) 2009-07-16
AU2008270300A1 (en) 2009-01-08
MA32120B1 (fr) 2011-03-01
KR20100039849A (ko) 2010-04-16
CA2692383A1 (en) 2009-01-08
MX2009013935A (es) 2010-01-28
US8889665B2 (en) 2014-11-18
PE20090837A1 (es) 2009-07-24
WO2009003999A2 (en) 2009-01-08
AR067397A1 (es) 2009-10-07
TN2009000551A1 (fr) 2011-03-31
BRPI0814601A2 (pt) 2019-09-24
EP2173734B1 (en) 2016-03-23
IL202625A0 (en) 2010-06-30
EA201000105A1 (ru) 2010-06-30
US20110183952A1 (en) 2011-07-28
JP2010531851A (ja) 2010-09-30
UY31198A1 (es) 2009-01-30
TW200911789A (en) 2009-03-16
ECSP099823A (es) 2010-01-29
CO6251316A2 (es) 2011-02-21
CN101796045A (zh) 2010-08-04

Similar Documents

Publication Publication Date Title
CL2008001943A1 (es) Compuestos derivados de fenil-triazol, inhibidores de enzimas de señales especificas que participan del control de la proliferacion celular; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer, infecciones, enfermedades inflamatorias y autoinmunes.
CL2011001215A1 (es) Compuestos derivados de pirimidina, inhibidores de tirosina quinasa; composiciones farmaceuticas que los comprenden; y su uso en el tratamiento y/o prevencion de cancer, enfermedades inflamatorias y enfermedades autoinmunes.
TW200800994A (en) Inhibitors of E1 activating enzymes
ECSP078013A (es) Inhibidores heterocíclicos de mek y métodos de uso de ellos
CL2010001637A1 (es) Compuestos derivados de isoindolonas; composición farmacéutica que los comprende; y su uso como inhibidores de la quinasa mek para tratar enfermedades hiperproliferativas y/o inflamatorias tales como cáncer, artritis reumatoidea entre otras.
BRPI0715176A8 (pt) compostos de heteroarila utéis como inibidores de enzimas de ativação e1
CL2008001633A1 (es) Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer.
CL2007001996A1 (es) Compuestos derivados de heteroarilos nitrogenados sustituidos con fenilo, inhibidores de la produccion de citoquinas; composicion farmaceutica que los comprende; y sus usos en el tratamiento del cancer, infecciones, enfermedades inflamatorias y autoinmunes.
CL2011000489A1 (es) Compuestos derivados de pirimido[5,4-d]pirimidina, los cuales actuan como inhibidores de tirosina-quinasas; y composiciones farmaceuticas que los comprenden, utiles en el tratamiento de enfermedades que se caracterizan por una proliferacion celular excesiva o anomala
CL2008001659A1 (es) Compuestos derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una enfermedad inmunologica seleccionada a partir de rechazo de trasplante de organo, lupus, esclerosis multiple, entre otras enfermedades.
CL2012003745A1 (es) Compuestos derivados de aminopirazoloquinazolinas, como inhibidores frente a la actividad fosforilante del receptor igf-1 localizado en membranas celulares; preparacion farmaceutica que los contiene; y su uso en el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
CL2008002397A1 (es) Compuestos derivados de imidazoles biciclicos fusionados; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar neoplasia benigna o maligna.
CL2007002316A1 (es) Compuestos derivados de pirimidina, inhibidores de pi3k; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en enfermedades proliferativas como cancer.
BR112012008624A2 (pt) inibidores de tirosina quinase de bruton
CL2008002319A1 (es) Compuestos derivados de pirrolopirimidina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
CL2011000691A1 (es) Compuestos derivados de nicotinamida sustituida; composicion farmaceutica que los comprende; uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
BRPI0807146B8 (pt) compostos inibidores da atividade da akt, seu uso no tratamento de câncer e artrite, bem como composição farmacêutica compreendendo os mesmos
CL2008003265A1 (es) Compuestos derivados de heterociclos nitrogenados, supresores de la produccion de colageno; composicion farmaceutica que comprende dichos compuestos; y su uso para prevenir y/o tratar la fibrosis y/o los tumores.
MX2022005411A (es) COMPUESTOS DE UNIÓN A IL-2RßYC.
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
CL2011000480A1 (es) Compuestos derivados de amino-1,2,4-triazolo[1,5-a]piridina sustituidos, inhibidores de quinasa; composicion farmaceutica; y su uso para el tratamiento o prevencion de condiciones inflamatorias, inmunologicas, autoinmunes, alergicas, reumaticas, tromboticas, cancer, infecciones, padecimientos neurodegenerativos, entre otras.
MX2009006706A (es) Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos.
UY32882A (es) (heteroarilmetil) tiohidantoínas sustituidas
CL2007003774A1 (es) Compuestos derivados de quinazolina sustituidos, inhibidores de quinasa; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, aterosclerosis y artritis.
CL2007003523A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad de pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso en el tratamiento profilactico o terapeutico del cancer